IMMUNE NETWORK

  • 제12권1호
  • /
  • Pages.33-39
  • /
  • 2012
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59

  • Hong, Jeong-Won (Department of Pathology, Chungbuk National University College of Medicine) ;
  • Cho, Woon-Dong (Department of Pathology, Chungbuk National University College of Medicine) ;
  • Hong, Kwon-Pyo (Department of Pathology, Chungbuk National University College of Medicine) ;
  • Kim, So-Seul (Department of Pathology, Chungbuk National University College of Medicine) ;
  • Son, Seung-Myoung (Department of Pathology, Chungbuk National University College of Medicine) ;
  • Yun, Seok-Joong (Department of Urology, Chungbuk National University College of Medicine) ;
  • Lee, Ho-Chang (Department of Pathology, Chungbuk National University College of Medicine) ;
  • Yoon, Sang-Soon (Research Institute of Dinona Inc.) ;
  • Song, Hyung-Geun (Department of Pathology, Chungbuk National University College of Medicine)
  • 투고 : 2012.01.12
  • 심사 : 2012.02.07
  • 발행 : 2012.02.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Therapeutic approaches using monoclonal antibodies (mAbs) against complement regulatory proteins (CRPs:i.e.,CD46,CD55 and CD59) have been reported for adjuvant cancer therapy. In this study, we generated a recombinant 1E8 single-chain anti-CD59 antibody (scFv-Fc) and tested anti-cancer effect.by using complement dependent cytotoxicity (CDC). Methods: We isolated mRNA from 1E8 hybridoma cells and amplified the variable regions of the heavy chain (VH) and light chain (VL) genes using reversetranscriptase polymerase chain reaction (RT-PCR). Using a linker, the amplified sequences for the heavy and light chains were each connected to the sequence for a single polypeptide chain that was designed to be expressed. The VL and VH fragments were cloned into the pOptiVEC-TOPO vector that contained the human CH2-CH3 fragment. Then, 293T cells were transfected with the 1E8 single-chain Fv-Fc (scFv-Fc) constructs. CD59 expression was evaluated in the prostate cancer cell lines using flow cytometry. The enhancement of CDC effect by mouse 1E8 and 1E8 scFv-Fc were evaluated using a cytotoxicity assay. Results: The scFv-Fc constructs were expressed by the transfected 293T cells and secreted into the culture medium. The immunoreactivity of the secreted scFv-Fc construct was similar to that of the mouse 1E8 for CCRF-CEM cells. The molecular masses of 1E8 scFv-Fc were about 120 kDa and 55 kDa under reducing and non-reducing conditions, respectively. The DNA sequence of 1E8 scFv-Fc was obtained and presented. CD59 was highly expressed by the prostate cancer cell line. The recombinant 1E8 scFv-Fc mAb revealed significantly enhanced CDC effect similar with mouse 1E8 for prostate cancer cells. Conclusion: A 1E8 scFv-Fc construct for adjuvant cancer therapy was developed.

키워드

참고문헌

  1. Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M, Vigar MA, van der Wetering S, Morgan BP, Troost D, Baas F: The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J Neurosci 27;7663-7672, 2007. https://doi.org/10.1523/JNEUROSCI.5623-06.2007
  2. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X: Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 104;550-558, 2009. https://doi.org/10.1161/CIRCRESAHA.108.191361
  3. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F: Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement- regulatory proteins CD55 and CD59. Eur J Immunol 35;2175-2183, 2005. https://doi.org/10.1002/eji.200425920
  4. Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, Mesa T, Nam S, Yu H, Jove R: Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 5;823-832, 2007. https://doi.org/10.1158/1541-7786.MCR-06-0352
  5. Shi XX, Zhang B, Zang JL, Wang GY, Gao MH: CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer. Cell Mol Immunol 6;61-66, 2009. https://doi.org/10.1038/cmi.2009.8
  6. Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, Schultz S, Kirschfink M: Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets 10;922-931, 2010. https://doi.org/10.2174/156800910793357952
  7. Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R: The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol 632;159-174, 2008.
  8. Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI: Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 108;930-936, 2004. https://doi.org/10.1002/ijc.11606
  9. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R, Meri S: Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 71;1049-1055, 1997. https://doi.org/10.1002/(SICI)1097-0215(19970611)71:6<1049::AID-IJC22>3.0.CO;2-7
  10. Sivasankar B, Longhi MP, Gallagher KM, Betts GJ, Morgan BP, Godkin AJ, Gallimore AM: CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy? J Immunol 182;5203-5207, 2009. https://doi.org/10.4049/jimmunol.0804243
  11. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, Shiramizu B, Halperin JA, Qin X: A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 184; 359-368, 2010. https://doi.org/10.4049/jimmunol.0902278
  12. Meri S, Waldmann H, Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65;532-537, 1991.
  13. Babiker AA, Nilsson B, Ronquist G, Carlsson L, Ekdahl KN: Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack. Prostate 62;105-114, 2005. https://doi.org/10.1002/pros.20102
  14. Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G: Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 62;224-232, 2005. https://doi.org/10.1002/pros.20134
  15. Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spendlove I: Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother 55;973-980, 2006. https://doi.org/10.1007/s00262-005-0055-0
  16. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F: In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67;10556-10663, 2007. https://doi.org/10.1158/0008-5472.CAN-07-1811
  17. Zhao WP, Zhu B, Duan YZ, Chen ZT. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 21;1405-1411, 2009.
  18. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S: Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 65;10562-10568, 2005. https://doi.org/10.1158/0008-5472.CAN-05-1894
  19. Vaughan TJ, Osbourn JK, Tempest PR: Human antibodies by design. Nat Biotechnol 16;535-539, 1998. https://doi.org/10.1038/nbt0698-535
  20. Hoogenboom HR, Chames P: Natural and designer binding sites made by phage display technology. Immunol Today 21;371-378, 2000. https://doi.org/10.1016/S0167-5699(00)01667-4
  21. Choi GH, Lee DH, Min WK, Cho YJ, Kweon DH, Son DH, Park K, Seo JH: Cloning, expression, and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli. Protein Expr Purif 35;84-92, 2004. https://doi.org/10.1016/j.pep.2003.12.008
  22. Cao M, Cao P, Yan H, Lu W, Ren F, Hu Y, Zhang S: Construction, purification, and characterization of anti- BAFF scFv-Fc fusion antibody expressed in CHO/dhfrcells. Appl Biochem Biotechnol 157;562-574, 2009. https://doi.org/10.1007/s12010-008-8434-6
  23. Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA: CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 15;2739-2746, 2009. https://doi.org/10.1158/1078-0432.CCR-08-1694
  24. Choi TH, Choi CW, Awh OD, Lim SM: Expression of the recombinant single-chain anti-B cell lymphoma antibody. J Biomed Lab Sci 9;111-121, 2003.
  25. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM: Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56;3055-3061, 1996.